health – Page 3 – Market Industry Forecast News

Obesity Treatment Market Driven by Government Initiatives to Curb Obesity Epidemic

The global obesity treatment market size is expected to reach USD 60.53 billion in 2030 and is anticipated to grow at a CAGR of 22.31% from 2025 to 2030. The upward trend in sedentary lifestyles, physical inactivity, and unhealthy food habits are the vital factors responsible for the high prevalence of obesity. According to the Institute of Health Metrics and Evaluation, about 30.0% of the global population is either obese or overweight.

Additionally, along with commercial availability of solutions for weight management, technological advancements introduced by the vertical players and supportive initiatives undertaken by the governments, create more awareness with regard to obesity and its impact on health. This is further driving the growth of the obesity treatment market.

There are various approaches for weight management such as diet, exercise, drugs, minimally invasive devices & implants, and surgeries. Amongst the prevalent drugs, the combination drugs hold the largest market share whereas satiety drugs that provide a feeling of fullness appear as the fastest-growing segment in the obesity treatment market.

In surgeries, gastric bypass procedures form the largest growing segment whereas the minimally invasive endoscopic procedure segment that involves surgical placement of implants and devices, such as satiety devices and gastric emptying devices, is the fastest-growing space.

Get a preview of the latest developments in the Obesity Treatment Market! Download your FREE sample PDF today and explore key data and trends

Intense competition in the private sector has driven advancements and innovation toward the development of the latest techniques for obesity treatment that are offered in private hospitals and clinics. As a result, the demand for minimally invasive procedures is swiftly increasing. In addition, increasing awareness of obesity & the associated diseases and the commercial availability of weight management solutions is propelling the obesity treatment market.

Obesity Treatment Market Report Highlights

Based on drug class, the industry has been categorized into GLP-1 receptor agonists, lipase inhibitors, appetite suppressants, and other drug classes
Based on the route of administration, the obesity treatment market has been categorized into parenteral and oral
Based on distribution channels, the market has been categorized into hospital pharmacies, retail pharmacies, and others.
The other pharmacies are expected to grow at a considerable growth of over the forecast period
North America obesity treatment market dominated the global industry with a revenue share of 73.39% in 2024

Key Obesity Treatment Company Insights

Some prominent players in the global market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis, Rhythm Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The market is shaped by mergers, acquisitions, and partnerships, along with significant investments in research & development to address unmet needs and expand treatment options.

Product innovation and regulatory approvals are key strategies for leading companies in the obesity treatment market to maintain a competitive edge. Established players focus on developing advanced therapies, such as next-generation GLP-1 receptor agonists and oral weight-loss drugs, while securing regulatory approvals to expand market reach. Meanwhile, emerging companies are targeting niche areas, including personalized obesity treatments and novel drug delivery mechanisms, to address unmet needs.

List of Key Players in Obesity Treatment Market

Novo Nordisk A/S
GlaxoSmithKline plc
VIVUS LLC
Currax Pharmaceuticals
Boehringer Ingelheim International GmbH
Rhythm Pharmaceuticals, Inc.
Gelesis
Eli Lilly and Company

Gather more insights about the market drivers, restrains and growth of the Global Obesity Treatment Market

U.S. Women’s Health Market Growth in Health Supplements and Nutritional Products

The U.S. women’s health market size is estimated to reach USD 24.36 billion by 2030, expanding at a CAGR of 3.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women’s health are being undertaken in the country, which involve advocating for policy changes, promoting girls’ education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Get a preview of the latest developments in the U.S. Women’s Health Market! Download your FREE sample PDF today and explore key data and trends

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women’s Health networks to address women’s health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women’s health.

U.S. Women’s Health Market Report Highlights

Based on drug, the Prolia drug segment held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
Based on age, the others age segment dominated the U.S. women’s health industry in 2024, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
Based on distribution channel, the hospital pharmacy segment dominated the market in 2024 due to the high stock and availability of women’s health therapeutics in the hospital pharmacies
Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

List of Key Players in U.S. Women’s Health Market

AbbVie, Inc.
Bayer AG
Merck & Co., Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Agile Therapeutics
Amgen, Inc.
Apothecus Pharmaceutical Corp.
Eli Lilly and Company
Ferring B.V.

Gather more insights about the market drivers, restrains and growth of the U.S. Women’s Health Market

Tumor Necrosis Factor Inhibitor Drugs Market Increasing Focus on Personalized Medicine

The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July 2023.

Get a preview of the latest developments in the Tumor Necrosis Factor Inhibitor Drugs Market! Download your FREE sample PDF today and explore key data and trends

Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights

By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.
In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.
The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.

Key Tumor Necrosis Factor Inhibitor Drugs Company Insights

Some key players in the market are AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., and others. These companies constantly invest in product innovation, such as developing biosimilars, focusing on personalized treatment methods to meet patient needs and enhance treatment productivity and satisfaction. Collaborative research initiatives with healthcare specialists and research institutes drive innovation and integration, which improves the outcomes so that they can stay at the forefront of industry trends.

AbbVie Inc. has been a prominent market leader for years and is well known for its ability to treat various autoimmune diseases, including rheumatoid arthritis and Crohn’s disease. AbbVie has introduced Humira, one of the best-selling drugs globally. It has positioned itself for many years, so it has a vast clinical database, which helps it adapt to the changing world with its research and development focusing on new therapies. This eventually allowed it to capitalize on emerging markets, and its market influence and physician acceptance also increased.
Johnson & Johnson Services’ major manufactured product is Remicade, which has been a cornerstone in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. The company’s long history and reputation contribute to its market growth and strength. By constantly investing in research and development, it finds new ways to develop new interpretations that can improve patient results and mark its presence as a prominent player in the market.

List of Key Players in the Tumor Necrosis Factor Inhibitor Drugs Market

AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services Inc.
UCB S.A.
Pfizer, Inc.
Novartis International AG
Boehringer Ingelheim Pharmaceuticals, Inc.
Merck & Co., Inc.

Gather more insights about the market drivers, restrains and growth of the Global Tumor Necrosis Factor Inhibitor Drugs Market

Synbiotic Product Market Impact of Digital Marketing on Consumer Engagement

The global synbiotic product market size is anticipated to reach USD 1.68 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.3% from 2025 to 2030. Increasing consumption of functional food and beverages around the world is the main factor expected to boost the demand for synbiotic products over the forecast period. In addition, rise in the consumption of probiotics and prebiotics owing to widespread awareness regarding health benefits in India, China, and Japan is expected to provide growth opportunity for the market in the near future.

Growing trend of fortifying functional food and beverages with prebiotics and probiotic ingredients to enhance nutritional content and product offerings will open new avenues for the market in coming years. For instance, in February 2020, Asmara, a Singapore brand owned by F&B consultancy company NU3x, will launch six functional powders containing synbiotics by the end of March, 2020. The products are designed to enhance immunity, cognitive health, energy, and vitality. Major vendors are adopting merger & acquisition strategies to enhance product offerings. For instance, in November 2019, Synbiotic Health entered into a licensing agreement with NUtech Ventures, the nonprofit technology commercialization affiliate of the University of Nebraska, to develop innovative synergistic synbiotics.

Get a preview of the latest developments in the Synbiotic Product Market! Download your FREE sample PDF today and explore key data and trends

Functional food and beverage emerged as the largest product segment with a share of 84.1% in 2019. Growing awareness among consumers regarding associated benefits of fortified functional food and beverages for the enhancement of gut health is projected to be a key factor for the segment growth. Additionally, increasing application of fortified food and beverages to improve immunity, cardiovascular health, and cognitive health is expected to provide growth opportunity for the segment over the forecast period. Dietary supplement is expected to witness the fastest growth over the forecast period. Increasing number of health conscious consumers is expected to support the growth of dietary supplements in coming years.

The offline segment held a leading market share in 2019. High availability at supermarket and hypermarket and pharmacy stores is the main factor expected to favor the sales of synbiotic products through the offline channel in coming years. While the popularity of online sales channel is steadily growing, around 83% of consumers prefer the offline channel as it provides the leverage of feel, touch, and taste, thus driving the sales of synbiotic products through offline channel.

Europe emerged as the largest regional market with a share of 37% in 2019. This is attributed to high awareness regarding health benefits, coupled with the availability of synbiotic products. Asia Pacific is expected to expand at the fastest CAGR of 9.5% from 2020 to 2027. Growing middle class population and rapid urbanization, along with growing awareness regarding health benefits of synbiotics, are the major factors expected to drive the regional market over the forecast period. Shifting consumer inclination towards functional food and beverages on account of rising incidence of cardiovascular disorders and surge in the number of weight management programs is expected to propel the demand for synbiotic products in coming years.

Synbiotic Product Market Report Highlights

Based on product, functional food & beverages dominated the market with the largest revenue share of 83.4% in 2024. Increasing fortification of food and beverages to enhance nutritional value is the main factor propelling the segment growth.
Online channel is expected to grow at the fastest CAGR over the forecast period. This is attributed to increasing consumer preferences for e-commerce and dependence of generation X, millennials, and generation Z parents on internet.
Europe dominated the synbiotic products market with a share of exceeding 35.1% in 2024 due to increasing consumption of functional food and beverages, along with growing awareness regarding health benefits of prebiotics and probiotics among the consumers.
Asia Pacific is expected to expand at the fastest CAGR of 9.5% over the forecast period on account of rising consumption of functional drinks in countries, like Japan, China, India, and New Zealand.

List of Key Players in the Synbiotic Product Market

Daflorn Ltd
Sabinsa
Danone
Yakult Honsha Co. Ltd
Probiotical S.p.A
United Naturals
Pfizer Inc.
Synbiotic Health
NUtech Ventures
Asmara (NU3x)

Gather more insights about the market drivers, restrains and growth of the Global Synbiotic Product Market

Medical X-ray Generators Market Focuses on User-Friendly Interfaces

The global medical X-ray generators market size is expected to reach USD 2.9 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.1% from 2023 to 2030. The unprecedented shift in lifestyle-associated habits coupled with increasing prevalence of chronic diseases is responsible for the rise in demand for accurate diagnostic tools, which is presumed to bolster the market growth. In addition, the global geriatric population base that is highly susceptible to developing these chronic diseases is anticipated to impel the demand for high-resolution imaging systems. This high requirement is effectively addressed by the use of medical X-ray generators, thus presenting the market with high growth potential throughout the forecast period. In addition, these devices lead to better patient outcomes, which include faster detection of disease conditions and improved patient safety profile. These associated benefits are expected to increase the overall adoption rate of medical X-ray generators over the coming years

Furthermore, technological advancements such as modification of the design of computer-controlled X-ray generator interface with imaging system result in better synchronization of the overall imaging system with X-ray generators. This has resulted in the application of medical X-ray generators in fluoroscopy, radiography, and angiography, thus widening the potential for growth during the forecast period. The outbreak of the COVID-19 pandemic led to a decline in research activities, the closure of universities and academic institutions, and a decline in clinical trial activities. The fear of virus spread also declined diagnostic or surgical activities at end-use settings. The economic crunch at hospitals, diagnostic centers, or clinics led to the reduced adoption of software and systems for non-invasive diagnosis. Thus, the pandemic led to a decline in the market in 2020.

Order a free sample PDF of the Medical X-ray Generators Market Intelligence Study, published by Grand View Research.

Medical X-ray Generators Market Report Highlights

By type, the stationary segment held the largest share of over 65.0% in 2022. This can be attributed to low costs, high stability, and durability associated with the device, which is responsible for the high adoption rate in hospital settings
By application, the cardiovascular segment held the largest share of over 15.0% in 2022. This is primarily a consequence of the increasing prevalence of cardiovascular diseases. In addition, the high demand for monoenergetic X-ray generators for cardiovascular imaging owing to the appropriate and safe intensity of energy projections is presumed to provide growth potential to the market
In 2022, North America held the largest share of over 35.0%. The presence of government regulatory authorities consistently striving toward high patient safety is a significant factor that is presumed to be responsible for the regional market growth

Regional Insights

North America dominated the overall market with a revenue share of over 35.0% in 2022 owing to the high physician preference for radiographic diagnostic procedures due to the greater patient safety associated with these procedures. In addition, the presence of government initiatives promoting patient safety is responsible for market growth across this region. Medical devices that cannot be manufactured in different regions continue to present lucrative opportunities for U.S.-based medical X-ray device exporters. The U.S. captured a substantial share of the North American market in 2022. Consistent efforts by market players and government organizations to pass through the market barriers for sustained export opportunities will drive the market in this region.

List of Key Players of the Medical X-ray Generators Market

Spellman High Voltage Electronics Corporation
Siemens Healthineers
Communications & Power Industries LLC
DRGEM Corporation
Innomed Medical Zrt.
DMS Group LLC
ECORAY
Josef Betschart AG
Poskom Co. Ltd.
SEDECAL
Neusoft Medical Systems
EMD Technologies
Nanning Yiju Medical Electronic Co. Ltd.

Gather more insights about the market drivers, restrains and growth of the Global Medical X-ray Generators Market

Limonene Market Highlights Global Trade Opportunities and Challenges

The global limonene market is expected to reach USD 497.61 million by 2030 to grow at a CAGR of 6.0% from 2023 to 2030 as per the new report by Grand View Research, Inc. The growth is majorly driven by the increasing demand for natural and eco-friendly products, the growing popularity of citrus flavors and fragrances, and the expanding applications of the product in various industries. The food and beverage industry is expected to be the largest market for the market, as it is widely used as a flavoring agent in a variety of food and beverage product, including soft drinks, juices, and alcoholic beverages. The cosmetics and cleaning industries are also significant consumers as it is widely used as a fragrance and cleaning agent in various personal care and cleaning products.

Companies in the market are investing in research and development to develop new and innovative products, expanding their geographic reach, increasing their production capacity, and adopting a forward integration strategy to remain competitive in the market. For instance, Firmenich has developed a range of limonene-based natural flavors and fragrances, while Givaudan has developed natural and sustainable flavors and fragrances. Citrosuco is one of the largest producers of orange juice and orange peel products in the world, offering a wide range of products, including orange oil and orange peel extract.

Order a free sample PDF of the Limonene Market Intelligence Study, published by Grand View Research.

In addition, the increasing popularity of aromatherapy and essential oils is expected to create new opportunities for the market. It is widely used in aromatherapy as a natural mood enhancer, stress reliever, and immune system booster. The rising popularity of aromatherapy and the growing awareness of the benefits of essential oils are expected to drive the demand for the product in the future.

Moreover, technological advancements in the production are expected to improve efficiency and reduce costs, therefore enabling more affordable and accessible market to consumers. Furthermore, the expanding applications in the pharmaceutical and agriculture industries are expected to offer new growth opportunities for companies operating in the market. For instance, some companies are using innovative techniques such as enzyme-mediated extraction and microwave-assisted extraction to extract limonene from citrus fruits, which is more efficient and cost-effective than traditional extraction methods.

Limonene Market Report Highlights

Lemon is the largest source segment which accounts for 33.8% by value in 2022. On the account of its use in various industry such as personal care, pharmaceuticals, cosmetics, and cleaning products. In addition, D-limonene, which is found in lemon oils, is used to treat cancer
Personal Care Products are the fastest growing end-use segment with a CAGR of 6.4%, due to its health benefits which help in reducing obesity, cancer, bronchitis, and other diseases
It is also being used as a bio pesticide in the agriculture industry, as it has insecticidal and herbicidal properties and is considered safer and more eco-friendly than synthetic pesticides
Europe is the fastest growing region with a CAGR of 6.6%. As the region is home to many cosmetics & personal care manufacturers and has thriving opportunities for manufacturers as the demand for bio-based products is growing
Florida Chemical Company has expanded its production capacity for citrus oils and derivatives to meet the growing demand from the food and beverage, cosmetics, and cleaning industries

List of Key Players in the Limonene Market

Lemonconcentrate S.L.U.
Florida Chemical Company (acquired by ADM)
Banner Chemicals Limited
Citrus Oleo
Sucorrico
Belize Ltd.
Spectrum Chemical
Citrosuco

Gather more insights about the market drivers, restrains and growth of the Global Limonene Market

Hospital Bed Management Systems Market Promotes Collaboration Across Departments

The global hospital bed management systems market size is expected to reach USD 3.8 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 10.31% from 2023 to 2030. The key factors driving the market growth include the rising incidence of chronic and infectious diseases, increasing geriatric population, and growing adoption of real-time bed management in hospitals. Furthermore, increasing awareness of hospital supportive and friendly software for smooth functioning of bed allotment and rising number of hospitals and clinics are contributing to the market growth. As a result, the demand for growing need for hospital bed management systems is expected to rise in the near future.

Hospitals lose quality suffering and millions due to cancellations, diversions and delays around bed management. The key challenges faced by hospitals include poor coordination among caregivers, lack of data on bed status resulting in hidden beds, inefficient discharge procedures, and deprived forecasting on bed demand from hospital wards, intensive care units, and other specialized areas. Hospital bed management systems are designed to help healthcare organizations manage and maintain their hospital beds.

Order a free sample PDF of the Hospital Bed Management Systems Market Intelligence Study, published by Grand View Research.

The software offers a variety of features including optimized bed management, allocation, and tracking for effective hospital management. These features focus on improved patient care, boost overall efficiency, and enhance resource utilization. In addition, hospital bed management systems offer automated workflows, real-time communications, escalation notifications, and reduced patient wait times by coordination.

Furthermore, major players in the market are undertaking several strategic initiatives owing to the rising adoption of automation technologies. For instance, in March 2023, Masimo and Temple Health entered into collaboration with focus on hospital automation and telehealth initiatives to improve life, improve patient outcomes, and reduce the cost of care. Similarly, LeanTaaS completed the acquisition of intelligent automation solutions provider Hospital IQ developing an AI-powered hospital operations software provider valued at about USD 1 billion.

Moreover, growing government funding and initiatives are anticipated to boost market growth. As per the HIMSS Future of Healthcare Report, 80% of healthcare providers plan to boost investments in technology and digital solutions within the next five years. This initiative is projected to drive growth in various sectors, including hospital automation technologies including hospital bed management systems.

Hospital Bed Management Systems Market Report Highlights

Based on the type, the market is segmented into acute care beds, critical care bed and long-term care bed, and others.
The acute care bed segment is anticipated to dominate the global market in 2022 and expected to grow at a fastest CAGR of 10.68% during the forecast period. The growth is attributed to increasing acute care admission of patients for one to three days at the healthcare facilities.
On the basis of deployment mode, the web & cloud-based segment dominated the market with a maximum revenue share in 2022. The growth is attributed to the need to reduce maintenance expenses and ensure the smooth operation of medical equipment.
North America dominated the market with a revenue share of 40.9% in 2022. The growth of the region is driven by factors such as the increase in the increasing investments in healthcare infrastructure, rise in disposable income, and the thriving medical tourism industry in the region.
The Asia Pacific region is predicted to experience significant growth during the forecast period, owing to large patient pool, increased end-user awareness, and heavy government investment in digital transformation in the region.

List of Key Players of Hospital Bed Management Systems Market

Oracle
Epic Systems Corporation
GE Healthcare
Veradigm LLC
CentralSquare Technologies
Advanced Data Systems
Terawe Corp
Lyngsoe Systems A/S
The Access Group
EMIS Health
TeleTracking Technologies, Inc.
SAP

Gather more insights about the market drivers, restrains and growth of the Global Hospital Bed Management Systems Market

Patient Engagement Solutions Market Challenges: Addressing User Adoption and Trust Issues

The global patient engagement solutions market was valued at approximately USD 22.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.7% from 2024 to 2030. Key drivers for this growth include ongoing technological advancements, the increasing adoption of Electronic Health Records (EHR) and mobile health (mHealth) solutions, the rising prevalence of chronic diseases, supportive initiatives from major stakeholders, and a growing consumer focus on healthcare. A survey conducted by NextGen Healthcare in 2021 revealed that 83% of ambulatory healthcare providers believe that patient engagement solutions are essential for achieving both financial success and improved patient outcomes, with the COVID-19 pandemic further accelerating market growth.

Gather more insights about the market drivers, restrains and growth of the Global Patient Engagement Solutions Market

Segmentation Analysis:

Delivery Type Insights

In 2023, the web and cloud-based segment dominated the market, holding a substantial 78.0% revenue share, and is projected to experience the fastest growth throughout the forecast period. The increasing adoption of these solutions is attributed to their ability to provide remote access to real-time data tracking, integrated features, easy accessibility, low handling costs, and straightforward data backup. Consequently, companies are increasingly investing in web and cloud-based patient engagement solutions. For instance, Microsoft introduced Microsoft Cloud for Healthcare in May 2020, aiming to enhance patient engagement and facilitate collaboration among healthcare teams through telehealth and data analytics capabilities.

On-premise services also play a crucial role, offering secure patient data management and ease of access, driven by the desire for comprehensive information access within healthcare facilities.

Component Insights

The software and hardware segment accounted for the largest revenue share of 62.7% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. These components form the core offerings of patient engagement solutions, providing intuitive user interfaces and continuous product upgrades that simplify installation, usage, and record retrieval. An example is FollowMyHealth from Allscripts, a widely used mobile-first, customizable patient engagement solution that enhances care quality and patient satisfaction.

The services segment is essential for the effective operation of patient engagement solutions, aiding in their optimization based on customer needs and maximizing health outcomes. This segment encompasses consulting, implementation, training, support and maintenance, as well as services related to interoperability and access to EHR data.

Functionality Insights

In 2023, the communication segment held the largest revenue share at 35.0%, forming the foundational offering of any patient engagement solution. This dominance is driven by the growing demand for telehealth, mHealth, and various virtual communication channels, including audio, video, and text. The pandemic accelerated the adoption of these virtual communication solutions, extending their applications to remote patient monitoring and mental health services.

The health tracking and insights segment is projected to grow at the fastest rate of 19.1% over the forecast period, fueled by the increasing integration of data analytics, artificial intelligence (AI), and machine learning to provide actionable insights for patients and their healthcare providers. For instance, Nuance Communications, Inc. introduced Nuance Mix, a conversational AI platform utilizing deep learning-based speech and natural language understanding technologies. In September 2021, Leidos partnered with Nuance to incorporate this platform and its omnichannel development tools into custom patient engagement solutions.

End-use Insights

The providers segment captured the largest revenue share, exceeding 47.0% in 2023. Providers, who cater to the highest volume of patients and serve as the primary point of contact for health consultations, are the leading adopters of patient engagement solutions. For example, in December 2021, Northwell Health in the U.S. implemented a patient engagement platform by Playback Health at select clinical sites, promoting mobility and secure sharing of point-of-care medical data.

Conversely, the payers segment is expected to grow at the fastest rate of 18.0% during the forecast period. The expansion of this segment is attributed to the increasing adoption of patient and customer engagement solutions that enable broad coverage and support value-based care delivery. Payers are focusing on managing patient care and ensuring connectivity at every stage of the treatment process.

Therapeutic Area Insights

Chronic disease management dominated the market in 2023, holding a revenue share of over 44.7%. The growing geriatric population in key markets, along with the rising prevalence of chronic diseases and accelerated adoption of digital technologies driven by the COVID-19 pandemic, have significantly contributed to the segment’s large share. Patient engagement solutions facilitate chronic disease management by enabling prevention and detection of conditions and supporting both provider-led and self-management strategies.

The health and wellness segment is projected to experience the fastest growth rate of 18.0% over the forecast period, driven by initiatives from leading companies, an expansion of product offerings covering mental health, weight management, and pregnancy, as well as increased research activities. For instance, in June 2023, Cardinal Health finalized an agreement to transfer its Outcomes business to Transaction Data Systems, enhancing patient engagement and clinical pharmacy solutions, thereby strengthening connections between payers and pharmaceutical companies within its extensive pharmacy network.

Application Insights

Outpatient health management accounted for over 39.0% of the market share in 2023, highlighting its dominance. The segment encompassing research and development (R&D) and preventive care is expected to grow at the fastest rate of 18.0% throughout the forecast period. Patients with chronic conditions require continuous monitoring and updates regarding their health management. The rise of healthcare consumerism has also led patients to become more engaged in care planning, tracking, and optimization.

Patient engagement solutions enable remote connections between patients and their healthcare providers, facilitating the efficient exchange of information, patient feedback, and other health-related data. For example, in November 2019, the CDC funded 13 state-level arthritis management and prevention programs to enhance the quality of life and monitoring for rural arthritis patients. Additionally, the adoption of patient engagement solutions for R&D purposes by medical device manufacturers, pharmaceutical companies, and other life sciences entities is expected to grow significantly due to increasing product availability and demand.

Order a free sample PDF of the Patient Engagement Solutions Market Intelligence Study, published by Grand View Research.

Non-small Cell Lung Cancer Therapeutics Market Predictions: What Lies Ahead in 2025

The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Access the Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Non-small Cell Lung Cancer Therapeutics Market Report Highlights

The adenocarcinoma segment dominated the market in 2023 with a share of 43.3% in 2023 due to increase in the population consuming tobacco and other products for smoking.

The targeted therapy segment dominated the market in 2023 with a share of 50.5% in 2023. The factors responsible for the market growth are the benefits of this therapy such as increased number of targeted therapeutics and low percentage of side effects during the treatment.

The hospital pharmacy segment dominated the market in 2023 with a share of 66.7% in 2023. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC.

North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.4% in 2023. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments.

Key Non-small Cell Lung Cancer Therapeutics Company Insights

Some of the major companies in the non-small cell lung cancer therapeutics market are F.Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. Companies are focusing on deploying new drugs and therapies in order to deal with the rising demand for lung cancer patients.

Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with health care providers, governments and local communities to support and expand access to health care around the world.

F.Hoffmann-La Roche Ltd. Is a multinational healthcare company that operates in the pharmaceutical and diagnostics divisions. The company is a major provider of cancer treatments globally.

Order your free sample copy of “Non-small Cell Lung Cancer Therapeutics Market Report 2024 – 2030, published by Grand View Research

Key Non-small Cell Lung Cancer Therapeutics Companies:

The following are the leading companies in the non-small cell lung cancer therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
GSK plc
Novartis AG
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.

Recent Developments

In May 2024, Pfizer Inc. announced longer-term follow-up results from the phase 3 CROWN trial evaluating LORBRENA versus XALKORI for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After 5 years of median follow-up, there was an 81% reduction in the disease progression rate.

In March 2023, F.Hoffmann-La Roche Ltd. announced the approval of VENTANA PD-L1 (SP263) Assay as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients. The company believed that with this launch, more patients will have access to an additional immunotherapy option.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com

Proton Therapy Systems Market Research: Understanding Patient Experience

The global proton therapy systems market size is expected to reach USD 1.2 billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030, according to a report by Grand View Research, Inc. The market is primarily driven by increasing number of proton therapy centers, rising number of cancer cases, and growing investments by hospitals to establish these centers.

Growing funds & investments by hospitals, manufacturers, and private investors are also contributing to the growth of this market. For instance, in August 2015, Mevion Medical Systems (U.S.) raised USD 200 million in an equity funding led by HOPU Investments (China) and YuanMing Capital (China). These funds are likely to be used for development of technologically advanced and low-cost products. Furthermore, governments across various geographies are including budgets for establishment of these centers. For instance, in July 2015, the state government of Victoria included nearly AUD 2 million (USD 1.53 million) to develop a National Centre for Proton Beam Therapy at the Victorian Comprehensive Cancer Centre (VCCC). The new center is expected to offer treatment to the patients in Australia.

Access the Proton Therapy Systems Market Size, Share & Trends Analysis Report By Product (Equipment, Services), By Type (Single-Room System, Multi-Room System), By Region, And Segment Forecasts, 2024 – 2030

In addition, rapid increase in the number of cancer cases globally is anticipated to bolster market growth during the forecast period. According to American Cancer Society, an estimated 1,688,780 new cancer cases are expected to be diagnosed in the U.S. and this disorder is likely to cause nearly 600,920 deaths in 2017. Furthermore, according to The Lancet, the number of women diagnosed with breast tumors is estimated to reach 3.2 million by 2030, which is almost double of 1.7 million in 2015.

Favorable reimbursement policies in the U.S and European countries and rising cancer-related healthcare expenditure in emerging nations is likely to propel the global proton therapy systems market. In addition, decreasing cost of proton therapy, increasing awareness, and rising adoption are expected to boost demand for these systems during the forecast period. However, high costs involved in the establishment of these centers and lack of reimbursement in emerging nations is likely to restrain growth in the coming years.

Proton Therapy Systems Market Report Highlights

The equipment segment held majority of the revenue share in 2023 due to rise in the number of contracts for establishment of proton therapy centers

The multi-room systems accounted for the largest market revenue share of 67.4% in 2030

North America proton therapy systems market dominated in 2023 and accounted for the market share of 42.7%.

Asia Pacific proton therapy systems market is estimated to register the fastest CAGR over the forecast period

Order your free sample copy of “Proton Therapy Systems Market Report 2024 – 2030, published by Grand View Research

Key Proton Therapy Systems Company Insights

Some key companies in the proton therapy systems market include IBA Worldwide, Optivus Proton Therapy, Inc., Hitachi, Ltd., and Sumitomo Heavy Industries, Ltd. Key companies are involved in strategic initiatives such as in innovating new products, collaborating with institutions and other industries, and establishing partnerships.

Hitachi Ltd. is a multinational company dedicated to manufacturing various electronic, communication, heavy electrical, and industrial machinery equipment. The company’s proton therapy systems provide cancer treatment using advanced technologies. The company has delivered proton therapy systems to hospitals such as the HKSH Medical Group, which are equipped with scanning technology.

Optivus Proton Therapy, Inc. provides healthcare services dedicated to the advancing proton therapy technology. The company offers proton therapy systems such as Conforma 3000, a sixth-generation proton beam technology, and Odessey, a treatment planning system now operating on the updated Odessey 5.0 updated version of the software.

Key Proton Therapy Systems Companies:

The following are the leading companies in the proton therapy systems market. These companies collectively hold the largest market share and dictate industry trends.

IBA Worldwide
Optivus Proton Therapy, Inc.
Mevion Medical Systems
Advanced Oncotherapy plc
Varian Medical Systems, Inc
ProTom International, Inc
Hitachi, Ltd.
Mitsubishi Corporation
ProNova Solutions, LLC
Sumitomo Heavy Industries, Ltd